Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients With RAS/BRAF Wild-Type, HER2-Positive, Metastatic Colorectal Cancer (S1613): A Randomized Phase II Trial

医学 西妥昔单抗 帕妥珠单抗 曲妥珠单抗 伊立替康 结直肠癌 肿瘤科 内科学 临床终点 危险系数 无进展生存期 癌症 福尔菲里 随机对照试验 化疗 乳腺癌 置信区间
作者
Kanwal Raghav,Katherine A. Guthrie,Benjamin Tan,Crystal S. Denlinger,Marwan Fakih,Michael J. Overman,Arvind Dasari,Larry Corum,Lee G. Hicks,Mital Patel,Benjamin Esparaz,Syed Mohammad Ali Kazmi,Nitya Alluri,Sarah Colby,Sepideh Gholami,Philip J. Gold,E. Gabriela Chiorean,Scott Kopetz,Howard S. Höchster,Philip A. Philip
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:43 (11): 1348-1357 被引量:9
标识
DOI:10.1200/jco-24-01710
摘要

PURPOSE ERBB2 overexpression/amplification in RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC; human epidermal growth factor receptor 2 [HER2]-positive mCRC) appears to be associated with limited benefit from anti-EGFR antibodies and promising responses to dual-HER2 inhibition; however, comparative efficacy has not been investigated. We conducted a randomized phase II trial to evaluate efficacy and safety of dual-HER2 inhibition against standard-of-care anti-EGFR antibody–based therapy as second/third-line treatment in HER2-positive mCRC. METHODS Patients with RAS/BRAF -WT mCRC after central confirmation of HER2 positivity (immunohistochemistry 3+ or 2+ and in situ hybridization amplified [HER2/CEP17 ratio >2.0]) were assigned (1:1) to either trastuzumab plus pertuzumab (TP; trastuzumab 6 mg/kg and pertuzumab 420 mg once every 3 weeks) or cetuximab plus irinotecan (CETIRI; cetuximab 500 mg/m 2 and irinotecan 180 mg/m 2 once every 2 weeks) until progression or unacceptable toxicity. Crossover to TP was allowed after progression on CETIRI. The primary end point was progression-free survival (PFS). Secondary end points included objective response rate (ORR), overall survival, safety, and HER2 gene copy number (GCN ≥20/<20) as a predictive factor. RESULTS Between October 2017 and March 2022, 54 participants were assigned to TP (n = 26) and CETIRI (n = 28). Median PFS did not vary significantly by treatment: 4.7 (95% CI, 1.9 to 7.6) and 3.7 (95% CI, 1.6 to 6.7) months in the TP and CETIRI groups, respectively. Efficacy of TP versus CETIRI differed significantly by HER2 GCN (median PFS, GCN ≥20 [9.9 v 2.9 months] and GCN <20 [3.0 v 4.2 months], respectively; P interaction = .003). On TP, ORR was 34.6% (57.1% with GCN ≥20 v 9.1% with GCN <20) with median GCN of 29.7 versus 13.2 for responders and nonresponders, respectively ( P = .004). Grade ≥3 adverse events occurred in 23.1% and 46.1% of participants with TP and CETIRI, respectively. CONCLUSION TP appears to be a safe and effective cytotoxic chemotherapy-free option for patients with RAS/BRAF -WT, HER2-positive mCRC. Higher levels of HER2 amplification were associated with greater degree of clinical benefit from TP vis-à-vis CETIRI.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
在水一方的应助被aaa采纳,获得10
1秒前
VDoo完成签到,获得积分10
2秒前
yeguo完成签到,获得积分10
2秒前
2秒前
2秒前
灰蓝天完成签到,获得积分10
2秒前
syvshc的应助被Vicky采纳,获得10
2秒前
2秒前
单纯之柔发布了新的文献求助10
2秒前
小浒完成签到,获得积分10
3秒前
明朗完成签到 ,获得积分10
3秒前
背后白柏完成签到 ,获得积分10
3秒前
tian完成签到,获得积分10
3秒前
hvtu发布了新的文献求助10
3秒前
4秒前
lion8603发布了新的文献求助10
4秒前
5秒前
5秒前
giao完成签到 ,获得积分10
5秒前
5秒前
MaYue发布了新的文献求助10
5秒前
如期而至完成签到,获得积分10
5秒前
TTTTT完成签到,获得积分10
5秒前
5秒前
大力一德完成签到,获得积分10
6秒前
今后的应助被细心的易文采纳,获得10
6秒前
悦悦发布了新的文献求助10
6秒前
彭于晏的应助被Yuwei采纳,获得10
6秒前
6秒前
hongzhihu完成签到,获得积分20
6秒前
落 风完成签到,获得积分10
6秒前
舒心的耷完成签到,获得积分10
7秒前
7秒前
香蕉觅云的应助被霁月采纳,获得10
7秒前
超级丸子完成签到,获得积分10
7秒前
优秀念柏完成签到,获得积分10
8秒前
8秒前
墨染完成签到,获得积分10
8秒前
研友_OWE完成签到,获得积分10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180586
求助须知:如何正确求助?哪些是违规求助? 9570581
关于积分的说明 21813457
捐赠科研通 7776777
什么是DOI,文献DOI怎么找? 3433294
关于科研通互助平台的介绍 2557547
邀请新用户注册赠送积分活动 2479253